| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA637: Ranibizumab for treating diabetic retinopathy |
|
Medicine details |
|
| Medicine name | ranibizumab (Lucentis®) |
| Formulation | intravitreal injection |
| Reference number | 2907 |
| Indication | Treatment of proliferative diabetic retinopathy in adults |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 03/02/2020 |
| NICE guidance | |